(Q27851406)

English

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

scientific article

In more languages

default for all languages

No label defined

No description defined

edit

Statements

1 reference

PubMed publication ID

17463250

retrieved

13 November 2016

title

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (English)

1 reference

stated in

PubMed

PubMed publication ID

13 November 2016

0 references

1 reference

14

0 references

Tetsuya Mitsudomi

series ordinal

3

0 references

Lewis C. Cantley

series ordinal

18

0 references

Pasi A Jänne

series ordinal

19

object named as

Pasi A Jänne

0 references

Tony Mok

object named as

Tony Mok

series ordinal

15

1 reference

stated in

ORCID Public Data File 2021

author name string

Jeffrey A Engelman

series ordinal

1

0 references

Kreshnik Zejnullahu

series ordinal

2

0 references

Youngchul Song

series ordinal

4

0 references

Courtney Hyland

series ordinal

5

0 references

Joon Oh Park

series ordinal

6

0 references

Neal Lindeman

series ordinal

7

0 references

Christopher-Michael Gale

series ordinal

8

0 references

Xiaojun Zhao

series ordinal

9

0 references

James Christensen

series ordinal

10

0 references

Takayuki Kosaka

series ordinal

11

0 references

Alison J Holmes

series ordinal

12

0 references

Andrew M Rogers

series ordinal

13

0 references

Charles Lee

series ordinal

16

0 references

Bruce E Johnson

series ordinal

17

0 references

publication date

18 May 2007

0 references

language of work or name

0 references

0 references

316

0 references

issue

5827

0 references

page(s)

1039-43

0 references

describes a project that uses

0 references

0 references

0 references

0 references

0 references

0 references

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Inhibition of the met receptor in mesothelioma

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1126/SCIENCE.1141478

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

(Q27851406)

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)